Tocilizumab for Treatment of Children and Young Adults With Severe Acute COVID-19: Experience at a Quaternary-care Children's Hospital. Issue 2 (29th October 2022)

• Record Type: Journal Article
• Authors: Teoh, Zheyi; Danziger-Isakov, Lara; Courter, Joshua D.; Frenck, Robert W.; Grimley, Michael S.; Marsh, Rebecca A.; Paulsen, Grant C.; Phillips, Christine L.; Spearman, Paul; Chima, Ranjit S.; Schulert, Grant S.
• Is Part Of: Pediatric infectious disease journal. Volume 42:Issue 2(2023)
• Page Start: 119
• Page End: 121
• Publication Date: 2022-10-29
• Subjects: child -- COVID-19 -- critical care -- intensive care units -- pediatrics -- tocilizumab; Communicable diseases in children -- Periodicals; Infection in children -- Periodicals; 618.929
• DOI: 10.1097/INF.0000000000003763
• Languages: English
• ISSNs: 0891-3668

Abstract

Abstract : We describe the clinical characteristics and outcomes of 16 children and young adults with severe acute COVID-19 who were treated with tocilizumab. Patients who were discharged by day 28 were more likely to be treated with tocilizumab earlier in their COVID-19 illness and had lower ferritin and interleukin-6 levels compared with those who were not discharged by day 28.